Читать «С ума сойти! Путеводитель по психическим расстройствам для жителя большого города» онлайн - страница 173

516

Rinne T, Westenberg HG, Den boer JA, Van den brink W. Serotonergic blunting to meta-chlorophenylpiperazine (m-CPP) highly correlates with sustained childhood abuse in impulsive and autoaggressive female borderline patients. Biol Psychiatry. 2000; 47(6): 548–56.

517

Herpertz SC, Dietrich TM, Wenning B, et al. Evidence of abnormal amygdala functioning in borderline personality disorder: a functional MRI study. Biol Psychiatry. 2001; 50(4): 292–8.

518

Gunderson JG, Sabo AN. The phenomenological and conceptual interface between borderline personality disorder and PTSD. Am J Psychiatry. 1993; 150(1): 19–27.

519

Twenge JM, Gentile B, Dewall CN, Ma D, Lacefield K, Schurtz DR. Birth cohort increases in psychopathology among young Americans, 1938–2007: A cross-temporal meta-analysis of the MMPI. Clin Psychol Rev. 2010; 30(2): 145–54.

520

Tebartz van elst L, Hesslinger B, Thiel T, et al. Frontolimbic brain abnormalities in patients with borderline personality disorder: a volumetric magnetic resonance imaging study. Biol Psychiatry. 2003; 54(2): 163–71.

521

Rausch J, Gäbel A, Nagy K, Kleindienst N, Herpertz SC, Bertsch K. Increased testosterone levels and cortisol awakening responses in patients with borderline personality disorder: gender and trait aggressiveness matter. Psychoneuroendocrinology. 2015; 55: 116–27.

522

Lenzenweger MF, Lane MC, Loranger AW, Kessler RC. DSM – IV personality disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007; 62(6): 553–64.

523

Zanarini MC, Frankenburg FR, Hennen J, Silk KR. The longitudinal course of borderline psychopathology: 6-year prospective follow-up of the phenomenology of borderline personality disorder. Am J Psychiatry. 2003; 160(2): 274–83.

524

Burcusa SL, Iacono WG. Risk for recurrence in depression. Clin Psychol Rev. 2007; 27(8): 959–85.

525

Kane JM, Jeste DV, Barnes TR: Tardive dyskinesia: A task force report of the American Psychiatric Association. Washington, D.C: American Psychiatric Association; 1992. Ref Type: Report.

526

Ebert A, Kolb M, Heller J, Edel MA, Roser P, Brüne M. Modulation of interpersonal trust in borderline personality disorder by intranasal oxytocin and childhood trauma. Soc Neurosci. 2013; 8(4): 305–13.

527

Bertsch K, Gamer M, Schmidt B, et al. Oxytocin and reduction of social threat hypersensitivity in women with borderline personality disorder. Am J Psychiatry. 2013; 170(10): 1169–77.

528

Amad A, Thomas P, Perez-rodriguez MM. Borderline Personality Disorder and Oxytocin: Review of Clinical Trials and Future Directions. Curr Pharm Des. 2015; 21(23): 3311–6.

529

Bateman A, Fonagy P. Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. Am J Psychiatry. 2001; 158(1): 36–42.

530

Bateman A, Fonagy P. Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder. Am J Psychiatry. 2009; 166(12): 1355–64.